The Hair in the Shower Drain

A familiar dread, back again

For a lot of mothers, the sight of hair collecting in the shower drain is not new. It is the same quiet dread that arrived a few months after giving birth. What surprises women on a GLP-1 is that it can return — sometimes a few months into meaningful weight loss — and that nobody warned them. It is one of the most searched side effects of this medication class, and one of the most misunderstood, in both directions: dismissed as vanity by people who have never watched it happen, and catastrophized online into permanent baldness by people watching it happen right now.

The salon notices before the prescriber does

The place this gets spotted first is usually not an exam room. It is a chair with a mirror in front of it and someone standing behind it who has washed the same head of hair every six weeks for a decade.

Three hairstylists interviewed by Fox News Digital in June 2025 described the same shift arriving in their books. Ashley DiMatteo, who owns a salon in Westchester, New York — and who takes a GLP-1 herself — put it flatly: "There has definitely been an increase in clients coming in with hair loss"¹. Becky Watt, an Ohio stylist of more than twenty years, described what it looks like at the sink: "I've seen thinning and shedding, and a lot of hair coming out very easily when being washed." Watt also offered, unprompted, the most useful clinical observation in the piece — a pattern in who it happens to: "It seems that my clients who say they don't have any appetite whatsoever are the ones losing the most hair."

Briana Delvecchio, a colorist at DiMatteo's salon, named the mechanism the way a stylist would: "It's a response to severe physical stress — and weight loss is considered starvation." The endocrinologist in the same report, Philip Rabito, said the quiet part in one line: "It is the rapidity of the weight loss that correlates with the amount of hair loss."

"Nobody warned me" is the most common sentence in this whole subject. It should not be, because two federal drug labels print the number.

What telogen effluvium actually is

Hair grows in cycles. At any moment most follicles are growing and a minority are resting, destined to shed. A significant physiological stress — childbirth, surgery, a high fever, rapid weight loss — can push an unusually large share of follicles into the resting phase at once. Two or three months later they let go together, and it looks alarming precisely because it is synchronized. That is telogen effluvium, and it is the same mechanism behind postpartum shedding, which is why it feels so eerily familiar.

The weight-loss link is measured, not assumed. In a retrospective study of 140 patients with telogen effluvium tied to weight loss, the mean loss was about 15% of body weight at a rate of roughly 3.5 kg a month — and 110 of the 140 were women². The authors' conclusion is the one that belongs in this magazine: women and older adults were especially vulnerable even when the degree of weight loss was no more severe than in men and younger patients.

The labels print a number — and it is not the same number for women

This is the part that turns "nobody warned me" into a fixable problem, because the warning already exists in writing.

In the pooled adult weight-loss trials in the Wegovy prescribing information, hair loss was reported in 3.3% of patients on semaglutide 2.4 mg versus 1% on placebo — and the label breaks that down by sex: 4% of women against 0.9% of men. At the newer 7.2 mg dose the figure rises to 5.8% overall, 8.4% in women against 0.2% in men³. (The same label also reports a pediatric trial at 4% versus no placebo-treated patients; that is the adolescent study, and its zero placebo arm is not an adult comparison.)

The Zepbound label tells the same story in the same shape: hair loss "reported more frequently in female than male patients," at 7.1% of women versus 0.5% of men, against 1.3% of women on placebo⁴. Both labels also state plainly that the hair-loss reactions "were associated with weight reduction" — the manufacturers themselves pointing at the loss rather than at the molecule.

So the honest reading of the labels is this: uncommon overall, roughly five to eight times likelier in women than in men, and rising with the dose that produces the fastest loss.

Is it the drug, or the weight loss?

For most of the last three years the confident answer was "the weight loss." That answer is still mostly right, and it is now less tidy than it was.

Two 2026 papers complicate it. A systematic review and meta-analysis of nine interventional studies covering 4,114 GLP-1 users found a significantly higher risk of hair loss than placebo — a risk ratio of about 3.3, rising to 3.6 when the analysis was restricted to trials in people with overweight or obesity — with a pooled event rate of 3.9%⁵. More awkward for the weight-loss-only explanation: a target trial emulation published in The BMJ looked at adults with type 2 diabetes, who lose far less weight, and still found more new alopecia on GLP-1s than on two comparator diabetes drugs — hazard ratios of 1.37 against SGLT-2 inhibitors and 1.68 against DPP-4 inhibitors, higher again when restricted to non-scarring alopecia. Its authors are careful to add that the absolute risk is low⁶. A systematic review lands in the same unfinished place: a real signal, strongest for semaglutide and tirzepatide, causality not yet established⁷.

None of that overturns telogen effluvium. It does mean the fair sentence is "mostly the speed of the loss — possibly not only that." A dermatology review of hair loss in GLP-1 patients adds the other half of the picture, which is how easy it is to undershoot protein and micronutrients on the way down⁸. Watt's observation from the salon chair — that the clients with no appetite at all shed the most — is the same finding, arrived at from the other end.

What actually helps

The most important intervention is also the least satisfying: time. Because the shed follicles are resting rather than dead, they typically re-enter the growth phase, and most women see regrowth over the months after weight and intake stabilize.

Beyond patience, the levers with any grounding are boring and worth doing anyway. Hit your protein target — this is the one place where "eat like someone who is trying to keep her hair" is literal advice rather than a slogan. Do not crash-diet on top of the medication; you are already in a deficit the drug is producing for you. Titrate at a pace your body can follow rather than racing to the top dose, which is the same argument the first-timer guide makes for other reasons. And ask a clinician to check the ordinary culprits — iron and ferritin, thyroid, vitamin D — that can worsen shedding independent of the drug and that are common in mothers regardless.

When to stop waiting

Telogen effluvium is diffuse, self-limited, and follows the loss by a couple of months. If your shedding is patchy rather than diffuse, if the scalp itself is scaling or scarring, if there is redness or pain, or if it is still worsening well past the expected window, that is not the pattern described above — and it is a reason to see a dermatologist rather than a supplement aisle.

None of it is a reason to abandon a medication that may be doing real good. It is a reason to go in knowing that the number is printed on the label, and that the label prints a different one for you than it does for your husband. If you are already deep in it and rattled, the rest of the adjustment is in our reporting on the "new body" and what it asks of you. A program with lab-guided dosing, like Optimized Health, can at least catch a nutrient deficiency alongside the weight loss — worth asking about regardless of which program you choose.